Chlvpp is as Effective as Alternating ChlvppAbod in Advanced Stage Hodgkin'S Disease

Acta Oncologica

Volumn 35, Issue sup8, 1996, Pages 73-80

  Holte, Harald ^a   Mella, Olav ^b   Wist, Ertk ^c   Telhaug, Ragnar ^d   Hannisdal, Einar ^a   Abrahamsen, Arne Foss ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Tromsø University   (United States)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PROCARBAZINE; PROGNOSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 0030440950     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841869609098523     Document Type: Article

References (45)

1. Urba W. J., Longo D. L. Medical progress: Hodgkin's disease. New Engl J Med 1992; 326: 678 – 87
2. DeVita V. T., Jr., Hubbard S. M. Hodgkin's disease. N Engl J Med 1993; 328: 560 – 5
3. Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990; 17: 716 – 35
4. Bartlett N. L., Rosenberg S. A., Hoppe R. T., Hancock S. L., Horning S. J. Brief chemotherapy, Stanford V. and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995; 13: 1080 – 8
5. van Leeuwen F. E., Jokman W. J., Hagenbeek A. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 1994; 12: 312 – 25
6. Abrahamsen J. F., Andersen A., Hannisdal E. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11: 255 – 61
7. Lund M. B., Kongerud J., Nome O. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 1995; 6: 495 – 501
8. Cooper J. A. D., Jr., White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321 – 40
9. Kantrowitz N. E., Bristow M. R. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984; 27: 195 – 200
10. Bauer K. A., Skarin A. T., Balikian J. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 1993; 74: 557 – 63
11. Minow R. A., Benjamin R. S., Lee E. T., Gottlieb J. A. Adriamycin cardiomyopathy—risk factors. Cancer 1977; 39: 1397 – 402
12. DeVita V. T., Jr. Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease?. No. Important Adv Oncol 1993; 197 – 208
13. Dady P. J., Mc E Iwain T. J., Austin D. E., Barrett A., Peckham M. J. Five years' experience with ChlVPP: Effective low-toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 1982; 45: 851 – 9
14. Santoro A., Bonadonna G., Bonfante V., Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770 – 5
15. DeVita V. T., Jr., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881 – 95
16. Lukes R. J., Craver L. F., Hall T. C. Report of the nomenclature committee. Cancer Res 1966; 26: 1311
17. McElwain T. J., Toy J., Smith E. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977; 3: 7 – 10
18. Bonadonna G., Zucali R., Monfardini S., DeLena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxam-ide versus MOPP. Cancer 1975; 36: 252 – 9
19. Cabanillas F., Hagemeister F. B., McLaughlin P. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407 – 12
20. Santoro A., Viviani S., Valagussa P., Bonfante V., Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 1986; 13: 23 – 6
21. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457 – 81
22. Peto R., Pike M. C., Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1 – 39
23. Dixon W. J., Brown M. B., Engelman L., Jennrich R. I. BMDP Statistical Software Manual. 1990
24. Longo D. L., Duffey P. L., DeVita V. T., Jr., Wesley M. N., Hubbard S. M., Young R. C. The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 1991; 9: 2042 – 51
25. Connors J. M. Is cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease?. Yes. Important Adv Oncol 1993; 95 – 189
26. Longo D. L., Duffey P. L., DeVita V. T., Jr. Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresis-tant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991; 9: 1409 – 20
27. Canellos G. P., Anderson J. R., Propert K. J. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478 – 84
28. Somers R., Carde P., Henry Amar M. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279 – 87
29. Radford J. A., Crowther D., Rohatiner A. Z. S., Ryder W. D. J., Gupta R. K., Oza A. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13: 2379 – 85
30. Druker B. J., Rosenthal D. S., Canellos G. P. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer 1989; 63: 1060 – 4
31. Gomez G. A., Panahon A. M., Stutzman L. Large mediastinal mass in Hodgkin's disease. Results of two treatment modalities. Am J Clin Oncol 1984; 7: 65 – 73
32. Crnkovich M. J., Leopold K., Hoppe R. T., Mauch P. M. Stage I to IIB Hodgkin's disease: The combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 1987; 5: 1041 – 9
33. Mauch P., Gorshein D., Cunningham J. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 1982; 66: 809 – 17
34. Pavlovsky S., Maschio M., Santarelli M. T. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80: 1466 – 73
35. Longo D. L., Russo A., Duffey P. L. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991; 9: 227 – 35
36. Austin-Seymour M. M., Hoppe R. T., Cox R. S., Rosenberg S. A., Kaplan H. S. Hodgkin's disease in patients over sixty years old. Ann Intern Med 1984; 100: 13 – 8
37. Specht L., Nissen N. I. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127 – 35
38. Eghbali H., Hoerni Simon G., de Mascarel I., Durand M., Chauvergne J., Hoerni B. Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years. Cancer 1984; 53: 2191 – 3
39. Walker A., Schoenfeld E. R., Lowman J. T., Mettlin C. J., MacMillan J., Grufferman S. Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment. Cancer 1990; 65: 1635 – 40
40. Erdkamp F. L., Breed W. P., Bosch L. J., Wijnen J. T., Blijham G. B. Hodgkin's disease in the elderly. A registry-based analysis. Cancer 1992; 70: 830 – 4
41. Enblad G., Glimelius B., Sundström C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol 1991; 2: 297 – 302
42. Peterson B. A., Pajak T. F., Cooper M. R. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889 – 98
43. van Leeuwen F. E., Chorus AM, Van den Belt J, Dusebout A. W. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063 – 73
44. Viviani S., Ragni G., Santoro A. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27: 1389 – 92
45. Clark S. T., Radford J. A., Crowther D., Swindell R., Shalet S. M. Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 1995; 13: 134 – 9